Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

IKT

Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:IKT
DatumZeitQuelleÜberschriftSymbolFirma
06/12/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IKTInhibikase Therapeutics Inc
05/12/202422h50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
05/12/202422h47Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:IKTInhibikase Therapeutics Inc
03/12/202412h24Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:IKTInhibikase Therapeutics Inc
18/11/202422h49Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IKTInhibikase Therapeutics Inc
18/11/202422h05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:IKTInhibikase Therapeutics Inc
14/11/202414h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IKTInhibikase Therapeutics Inc
08/11/202422h07Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:IKTInhibikase Therapeutics Inc
28/10/202422h26Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
28/10/202421h00Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
25/10/202423h52Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
25/10/202423h50Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
24/10/202401h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
24/10/202401h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
24/10/202401h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
24/10/202401h40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
24/10/202401h38Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
24/10/202401h35Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
18/10/202401h00Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
17/10/202422h05Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
10/10/202423h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
09/10/202414h40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
14/08/202422h25GlobeNewswire Inc.Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period ActivityNASDAQ:IKTInhibikase Therapeutics Inc
14/08/202422h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IKTInhibikase Therapeutics Inc
07/08/202414h00GlobeNewswire Inc.Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024NASDAQ:IKTInhibikase Therapeutics Inc
18/07/202423h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
18/07/202423h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
18/06/202423h27Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:IKTInhibikase Therapeutics Inc
17/06/202414h05GlobeNewswire Inc.Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s DiseaseNASDAQ:IKTInhibikase Therapeutics Inc
10/06/202422h20Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:IKTInhibikase Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:IKT

Kürzlich von Ihnen besucht

Delayed Upgrade Clock